Cargando…

Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States

BACKGROUND AND OBJECTIVES: Abaloparatide (ABL) significantly increases bone mineral density in men with osteoporosis similar to what was reported in postmenopausal women with osteoporosis. The cost effectiveness of sequential treatment with ABL followed by alendronate (ALN) in men at high fracture r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hiligsmann, Mickaël, Silverman, Stuart S., Singer, Andrea J., Pearman, Leny, Mathew, Jake, Wang, Yamei, Caminis, John, Reginster, Jean-Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232643/ https://www.ncbi.nlm.nih.gov/pubmed/37086385 http://dx.doi.org/10.1007/s40273-023-01270-x

Ejemplares similares

FRI682 Cost Effectiveness Of Four Treatment Approaches For US Women And Men At Very High Risk Of Osteoporotic Fractures
por: Hiligsmann, Mickael, et al.
Publicado: (2023)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
por: Greenspan, Susan L., et al.
Publicado: (2020)

ERRATUM for “Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis”
Publicado: (2020)

Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review
por: Li, Nannan, et al.
Publicado: (2023)

Correction to: Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review
por: Li, Nannan, et al.
Publicado: (2023)

The Efficacy and Safety of Abaloparatide‐SC in Men With Osteoporosis: A Randomized Clinical Trial
por: Czerwinski, Edward, et al.
Publicado: (2022)

Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual‐Energy X‐Ray Absorptiometry (DXA)
por: Winzenrieth, Renaud, et al.
Publicado: (2022)

The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis
por: Hiligsmann, Mickael, et al.
Publicado: (2020)

Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures
por: Ethgen, Olivier, et al.
Publicado: (2015)

Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
por: Hiligsmann, M., et al.
Publicado: (2021)

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
por: Bone, Henry G, et al.
Publicado: (2018)

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
por: McClung, Michael R., et al.
Publicado: (2017)

Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
por: McClung, Michael R., et al.
Publicado: (2018)

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend
por: Deal, Chad L., et al.
Publicado: (2019)

Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan
por: Mori, Takahiro, et al.
Publicado: (2021)

An Evaluation of Treatment Patterns for Osteoporosis and Outcomes After a Fragility Fracture in a Real-World Setting
por: Singer, Andrea J., et al.
Publicado: (2023)

Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis
por: Reginster, J. -Y., et al.
Publicado: (2019)

A scoping review of the public health impact of vitamin D-fortified dairy products for fracture prevention
por: Hiligsmann, Mickael, et al.
Publicado: (2017)

OR03-1 The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
por: Lane, Nancy, et al.
Publicado: (2019)

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
por: Reginster, Jean-Yves, et al.
Publicado: (2018)

Effective communication regarding risk of fracture for individuals at risk of fragility fracture: a scoping review
por: Beaudart, Charlotte, et al.
Publicado: (2021)

Abaloparatide Real‐World Patient Experience Study
por: Gold, Deborah T, et al.
Publicado: (2021)

Cost-effectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures
por: Ethgen, O., et al.
Publicado: (2015)

An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis
por: Li, Nannan, et al.
Publicado: (2020)

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide
por: Mori, Takahiro, et al.
Publicado: (2019)

Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan
por: Mori, Takahiro, et al.
Publicado: (2021)

Abaloparatide and the Spine: A Narrative Review
por: Thompson, Jeremy C, et al.
Publicado: (2020)

SAT-519 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture Representative of Covered Commercial Insurance Enrollees
por: Saag, Kenneth, et al.
Publicado: (2019)

Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
por: Hiligsmann, M., et al.
Publicado: (2019)

Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial
por: Cosman, Felicia, et al.
Publicado: (2020)

Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide
por: Tan, Juan, et al.
Publicado: (2019)

Management of patients at very high risk of osteoporotic fractures through sequential treatments
por: Curtis, Elizabeth M., et al.
Publicado: (2022)

Abaloparatide versus teriparatide: a head to head comparison of effects on fracture healing in mouse models
por: Bernhardsson, Magnus, et al.
Publicado: (2018)

Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
por: Watts, N.B., et al.
Publicado: (2019)

SUN-385 Differential Effects of Abaloparatide and Teriparatide on Hip Cortical Volumetric BMD by DXA-Based 3d Modeling
por: Winzenrieth, Renaud, et al.
Publicado: (2020)

Atypical fracture of the ulna associated with alendronate use
por: Bjørgul, Kristian, et al.
Publicado: (2011)

Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis
por: Tella, Sri Harsha, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_glo1le2fdodvamro91o83l4g8n